TriangleFOR PATIENTS · SOURCE READING
Treatment of Relapsed Chronic Myeloid Leukemia
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
In relapsed chronic myeloid leukemia (CML), the number of blast cells increases after a remission. Treatment of relapsed CML may include targeted therapy (ponatinib or asciminib).
Source links and citations
Learn more about these treatments in the Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice